MyFinsight
Home
Blog
About
Net income
$154,000K
(16.84%↑ Y/Y)
Depreciation
$45,700K
(12.01%↑ Y/Y)
Stock-based compensation
$10,900K
(47.30%↑ Y/Y)
Asset impairments
$3,900K
(2.63%↑ Y/Y)
Non-cash restructuring
charges
$1,000K
(25.00%↑ Y/Y)
Amortization
$500K
(-16.67%↓ Y/Y)
Net cash provided by
operating activities
$124,000K
(-29.98%↓ Y/Y)
Canceled cashflow
$92,000K
Net (decrease)
increase in cash and cash...
-$85,600K
(-181.14%↓ Y/Y)
Canceled cashflow
$124,000K
Borrowings under revolving
credit agreements
$50,000K
Proceeds from
stock-based compensation...
$6,900K
(97.14%↑ Y/Y)
Employee stock purchase
plan contributions
$1,900K
(11.76%↑ Y/Y)
Changes in assets and
liabilities
$86,000K
(1997.56%↑ Y/Y)
Other non-cash items,
net
$6,000K
(50.00%↑ Y/Y)
Net cash used in
financing activities
-$164,800K
(-1006.04%↓ Y/Y)
Canceled cashflow
$58,800K
Net cash used in
investing activities
-$43,200K
(42.55%↑ Y/Y)
Effect of exchange
rates on cash
-$1,600K
(-108.65%↓ Y/Y)
Shares purchased under
share repurchase...
$156,700K
(31240.00%↑ Y/Y)
Repayments under revolving
credit agreements
$50,000K
Dividend payments
$15,700K
(3.97%↑ Y/Y)
Excise tax payments
$800K
(-80.95%↓ Y/Y)
Principal repayments on
finance leases
$400K
(33.33%↑ Y/Y)
Capital expenditures
$43,200K
(-42.55%↓ Y/Y)
Back
Back
Cash Flow
West_Pharmaceutical_Services_Logo-svg
WEST PHARMACEUTICAL SERVICES INC (WST)
West_Pharmaceutical_Services_Logo-svg
source: myfinsight.com
WEST PHARMACEUTICAL SERVICES INC (WST)